MSc in Physics, Fernando has more than 25 years of new business launch leadership across business development, internationalization and M&A, both as an entrepreneur (he has founded 5 companies so far) as well as in global management position in multinational companies such as Ericsson or Hewlett Packard. Fernando is also partner of Hasten Ventures and member of the board of various technology and biotech firms such as Osatek SA., Irisbond SL., Prospero Biosciences SL. or Nito Inc.

Veronique Calleja obtained her PhD in 1999 in Molecular and Cellular Biology and Biochemistry from the University of Nice-Sophia Antipolis (INSERM U145), France. She moved to the London Research Institute (LRI) and Imperial College, Cancer Research UK to work on the RAS/PI3K/Akt signalling pathway and gene therapy for cancer.
In 2003 she was appointed Senior Scientific Officer at the LRI, London UK in the Cell Biophysics Laboratory where she used FRET-FLIM quantitative imaging to investigate the molecular mechanisms of PDK1/Akt signalling, structure and function.
In 2016 she was appointed Principal Laboratory Research Scientist in the laboratory of Prof Peter Parker at the Francis Crick Institute in London where she worked on a genetically modified mouse model harbouring an oncogenic mutation of PKCA.
She is a member of the Editorial Advisory board of the Biochemical Journal in Signal Knowledge Environment since 2011. She is the CSO of Hawk Biosystems since October 2021.

Borja has a Degree in Economics and Business Studies, Msc in Finance and Ma in Health Administration and Management. He has more than 20 years of experience in the Finance sectors such as Technology, Chemical and Automotive in small companies and multinationals such as Ericsson, Sun Chemical or Megatech Group.

Dr Juan Gumuzio obtained his PhD in Molecular Biology from the University of the Basque Country. His research has focused on breast cancer stem cell biology and 3D cell culture applications for drug development against cancer. He has gained experience in R&D and customer project management at the biotechnology start-up Stemtek Therapeutics. He has been a project manager and advisor at BIOEF (Basque Foundation for Health Innovation and Research).

James undertook an industrial PhD facilitated by Hawk Biosystems. The academic aspect of this PhD was a cotutelle between the University of the Basque Country and the University of Bordeaux. The PhD was supervised by Prof. Banafshe Larijani (Cell Biophysics Laboratory) and Prof. Antoine Italiano (Institut Bergonié). During his doctoral studies, James sought to elucidate PD-1/PD-L1 as a prognostic biomarker in a range of solid tumours. James graduated in 2022 with his PhD and continued his full-time role as our Product Manager.

Prof. Antonio Ferrer Montiel holds a PhD in Chemistry from the University of Alicante. He was appointed as full Professor of Biochemistry and Molecular Biology in the University Miguel Hernández (Elche) in 2007, and Director of the Institute of Molecular and Cellular Biology since 2011. His work has focused on the field of sensory neurobiology, principally on the molecular and cellular mechanisms contributing to chronic pain, with a particular interest in cancer and chemotherapy-induced pain. He is also involved in entrepreneurial activity, is the co-founder of 2 spin-offs and 2 start-up companies, and the inventor of 20 patents. He currently has 2 products in clinical development (Phase II) and one in pre-clinical. He was elected President of the Spanish Society of Biophysics in 2014, and he has been the coordinator of the Spanish Network on Ion Channels since 2008. He was also elected as a member of the University Miguel Hernández Governance Board in 2015.

Professor Peter Parker was awarded a DPhil in Biochemistry from Oxford in 1979. Following post-doctoral fellowships, and tenure-track appointment, he became a Principal Scientist at the Imperial Cancer Research Fund (to become Cancer Research UK) in 1990, and has held a joint appointment with King’s College London since 2006. His research work in cancer, along with the co-founding of companies, has led to broad interests and expertise in the dysregulation of cellular controls, in drug discovery and in biomarkers pertinent to oncology. He was elected to the European Molecular Biology Organisation in 1997, to the Academy of Medical Sciences in 2000, he was awarded the Morton Prize in 2004, elected to the Royal Society in 2006 and elected to the European Academy of Cancer Sciences in 2011. Peter is currently Director of the CRUK KHP Cancer Centre at King’s College London and is a Senior Group Leader at the Francis Crick Institute.

PhD in Chemistry, MBA from ESADE business school. In 1987, Antonio Parente cofounded the Grupo Lipotec, which was sold years later in one of the biggest transactions of the Spanish biotech sector. Antonio has also created other 5 additional companies (DiverDrugs, Primaderm, Lipofoods, BCN Peptides and GP Pharm). Having been the promoter and, for many years, President of Catalonia Bio / BioCAT (Catalan Association of Biotechnologies Companies), nowadays, Antonio is leading GP Pharm and BCN Peptides.

MSc in Physics, Fernando has more than 25 years of new business launch leadership across business development, internationalization and M&A, both as an entrepreneur (he has founded 5 companies so far) as well as in global management position in multinational companies such as Ericsson or Hewlett Packard. Fernando is also partner of Hasten Ventures and member of the board of various technology and biotech firms such as Osatek SA., Irisbond SL., Prospero Biosciences SL. or Nito Inc.

Prof. Alfredo Carrato, MD and PhD Head of the Medical Oncology Unit at the Hospital Universitario Ramon y Cajal (Madrid, Spain). His work is developed in the field of the clinical and basic research, especially in the area of digestive tract tumours (TTD), being a prominent member of the Spanish Group for Research in TTD with more than 200 publications. He is president of the Spanish Association for Research on Cancer (ASEICA).

Prof. Erick J Dufourc holder of PhD in Biophysics from the University of Ottawa/National Research Council, Canada. 1998 he was among the founders of the European Institute of Chemistry and Biology (IECB). In 2006 he created and directed the Institute of Chemistry and Biology of Membranes and Nanoobjects (CBMN), an interdisciplinary institute gathering 200 chemists, physicists and biologists in Bordeaux. Currently is the Deputy Scientific Director of Institut de Chimie CNRS – Paris France.

BA in Natural Sciences by the University of Cambridge, Raj is a serial entrepreneur with over 20 years´ experience in identifying, nurturing and fundraising for immunology and oncology focused technologies. Business development professional having built lasting partnerships. Extensive experience gathered along the way in pre-clinical drug discovery, diagnostics, biological and cell-based therapeutics. Today, Raj is Entrepreneur in Residence at the Venture Capital firm Apple Tree Partners in London.

BA in Natural Sciences by the University of Cambridge, Raj is a serial entrepreneur with over 20 years´ experience in identifying, nurturing and fundraising for immunology and oncology focused technologies. Business development professional having built lasting partnerships. Extensive experience gathered along the way in pre-clinical drug discovery, diagnostics, biological and cell-based therapeutics. Today, Raj is Entrepreneur in Residence at the Venture Capital firm Apple Tree Partners in London.

Professor Peter Parker was awarded a DPhil in Biochemistry from Oxford in 1979. Following post-doctoral fellowships, and tenure-track appointment, he became a Principal Scientist at the Imperial Cancer Research Fund (to become Cancer Research UK) in 1990, and has held a joint appointment with King’s College London since 2006. His research work in cancer, along with the co-founding of companies, has led to broad interests and expertise in the dysregulation of cellular controls, in drug discovery and in biomarkers pertinent to oncology. He was elected to the European Molecular Biology Organisation in 1997, to the Academy of Medical Sciences in 2000, he was awarded the Morton Prize in 2004, elected to the Royal Society in 2006 and elected to the European Academy of Cancer Sciences in 2011. Peter is currently Director of the CRUK KHP Cancer Centre at King’s College London and is a Senior Group Leader at the Francis Crick Institute.

Starting in the field of Chemistry and obtaining a BSc in 1991 from Uppsala University, Ola Söderberg then moved on to Biochemistry and obtained his PhD in 1997 in the Department of Pathology on “Regulation of Growth, Differentiation and Survival of B-Chronic Lymphocytic Leukemia Cells”. After completing several placements as post-doctoral researcher at IPATIMUP (Porto, Portugal) and Linköping University (Sweden) he returned to Uppsala in 2001. There, he was appointed Associate Professor in 2007 and then Senior Lecturer in 2013. In 2016 he became Professor in Molecular Proteomics and moved in 2017 to the department of Pharmaceutical Biosciences at Uppsala University, where he is now Professor in Pharmaceutical Cell Biology. His research mainly focuses on the development of new methods for visualization of protein activity in single cells. He is author of more than 100 scientific papers and inventor of 6 patents among them several versions of proximity ligation assay (PLA).